schliessen

Filtern

 

Bibliotheken

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

A liposome-encapsulated form of doxorubicin (TLC D-99), which was shown in preclinical toxicology to be less toxic to the gastrointestinal tract and myocardium than free doxorubicin, was administered by constant infusion (1.00-1.80 h) to 38 patients in single doses of 20, 30, 45, 60, 75, and 90 mg/m... Full description

Journal Title: Cancer research June 15, 1993, Vol.53(12), pp.2796-2802
Main Author: Cowens, J W
Other Authors: Creaven, P J , Greco, W R , Brenner, D E , Tung, Y , Ostro, M , Pilkiewicz, F , Ginsberg, R , Petrelli, N
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-5472
Link: http://search.proquest.com/docview/75769112/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest75769112
title: Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
format: Article
creator:
  • Cowens, J W
  • Creaven, P J
  • Greco, W R
  • Brenner, D E
  • Tung, Y
  • Ostro, M
  • Pilkiewicz, F
  • Ginsberg, R
  • Petrelli, N
subjects:
  • Adult–Administration & Dosage
  • Aged–Adverse Effects
  • Doxorubicin–Pharmacokinetics
  • Drug Administration Schedule–Chemically Induced
  • Drug Carriers–Chemically Induced
  • Female–Blood
  • Humans–Drug Therapy
  • Leukopenia–Metabolism
  • Liposomes–Chemically Induced
  • Male–Chemically Induced
  • Middle Aged–Chemically Induced
  • Nausea–Chemically Induced
  • Neoplasms–Chemically Induced
  • Thrombocytopenia–Chemically Induced
  • Vomiting–Chemically Induced
  • Drug Carriers
  • Liposomes
  • Doxorubicin
ispartof: Cancer research, June 15, 1993, Vol.53(12), pp.2796-2802
description: A liposome-encapsulated form of doxorubicin (TLC D-99), which was shown in preclinical toxicology to be less toxic to the gastrointestinal tract and myocardium than free doxorubicin, was administered by constant infusion (1.00-1.80 h) to 38 patients in single doses of 20, 30, 45, 60, 75, and 90 mg/m2 every 3 weeks and daily for 3 days at doses of 20, 25, and 30 mg/m2/day. The dose-limiting toxicity was leucopenia: the maximum tolerated doses were one at 90 mg/m2 and three at 25 mg/m2/day. Nausea, vomiting, and stomatitis were minimal or absent at each dose; alopecia was minor. Fever and chills were noted at most of the doses, and malaise was seen in some patients, especially at the higher doses. No hepatic, renal, or other organ toxicities were observed. Clinical cardiac toxicity was not observed in any patient; however, the cumulative doxorubicin dose was greater than 400 mg/m2 in only one patient. There was large variation among patients in estimated pharmacokinetic parameters and profiles. Higher plasma levels and dose intensities were achieved with TLC D-99 than were predicted for free doxorubicin. Liposome-encapsulated doxorubicin was well tolerated and produced less nausea, vomiting, and stomatitis than would be expected with free doxorubicin administered at equally myelosuppressive doses.
language: eng
source:
identifier: ISSN: 0008-5472
fulltext: fulltext
issn:
  • 00085472
  • 0008-5472
url: Link


@attributes
ID1300228661
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid75769112
sourceidproquest
recordidTN_proquest75769112
sourcesystemOther
pqid75769112
display
typearticle
titleInitial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
creatorCowens, J W ; Creaven, P J ; Greco, W R ; Brenner, D E ; Tung, Y ; Ostro, M ; Pilkiewicz, F ; Ginsberg, R ; Petrelli, N
contributorCowens, J W (correspondence author) ; Cowens, J W (record owner)
ispartofCancer research, June 15, 1993, Vol.53(12), pp.2796-2802
identifierISSN: 0008-5472
subjectAdult–Administration & Dosage ; Aged–Adverse Effects ; Doxorubicin–Pharmacokinetics ; Drug Administration Schedule–Chemically Induced ; Drug Carriers–Chemically Induced ; Female–Blood ; Humans–Drug Therapy ; Leukopenia–Metabolism ; Liposomes–Chemically Induced ; Male–Chemically Induced ; Middle Aged–Chemically Induced ; Nausea–Chemically Induced ; Neoplasms–Chemically Induced ; Thrombocytopenia–Chemically Induced ; Vomiting–Chemically Induced ; Drug Carriers ; Liposomes ; Doxorubicin
languageeng
source
descriptionA liposome-encapsulated form of doxorubicin (TLC D-99), which was shown in preclinical toxicology to be less toxic to the gastrointestinal tract and myocardium than free doxorubicin, was administered by constant infusion (1.00-1.80 h) to 38 patients in single doses of 20, 30, 45, 60, 75, and 90 mg/m2 every 3 weeks and daily for 3 days at doses of 20, 25, and 30 mg/m2/day. The dose-limiting toxicity was leucopenia: the maximum tolerated doses were one at 90 mg/m2 and three at 25 mg/m2/day. Nausea, vomiting, and stomatitis were minimal or absent at each dose; alopecia was minor. Fever and chills were noted at most of the doses, and malaise was seen in some patients, especially at the higher doses. No hepatic, renal, or other organ toxicities were observed. Clinical cardiac toxicity was not observed in any patient; however, the cumulative doxorubicin dose was greater than 400 mg/m2 in only one patient. There was large variation among patients in estimated pharmacokinetic parameters and profiles. Higher plasma levels and dose intensities were achieved with TLC D-99 than were predicted for free doxorubicin. Liposome-encapsulated doxorubicin was well tolerated and produced less nausea, vomiting, and stomatitis than would be expected with free doxorubicin administered at equally myelosuppressive doses.
version2
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/75769112/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Cowens, J W
1Creaven, P J
2Greco, W R
3Brenner, D E
4Tung, Y
5Ostro, M
6Pilkiewicz, F
7Ginsberg, R
8Petrelli, N
titleInitial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
subject
0Adult–Administration & Dosage
1Aged–Adverse Effects
2Doxorubicin–Pharmacokinetics
3Drug Administration Schedule–Chemically Induced
4Drug Carriers–Chemically Induced
5Female–Blood
6Humans–Drug Therapy
7Leukopenia–Metabolism
8Liposomes–Chemically Induced
9Male–Chemically Induced
10Middle Aged–Chemically Induced
11Nausea–Chemically Induced
12Neoplasms–Chemically Induced
13Thrombocytopenia–Chemically Induced
14Vomiting–Chemically Induced
15Drug Carriers
16Liposomes
17Doxorubicin
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Environmental Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Agricultural & Environmental Science Database
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest75769112
issn
000085472
10008-5472
rsrctypearticle
creationdate1993
addtitleCancer research
searchscope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
scope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
lsr43
01007489false
11007527false
21007944false
310000004false
410000006false
510000038false
610000043false
710000050false
810000120false
910000159false
1010000198false
1110000200false
1210000209false
1310000217false
1410000234false
1510000238false
1610000253false
1710000260false
1810000270false
1910000271false
2010000302false
contributorCowens, J W
startdate19930615
enddate19930615
citationpf 2796 pt 2802 vol 53 issue 12
lsr30VSR-Enriched:[description, eissn, pqid]
sort
titleInitial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
authorCowens, J W ; Creaven, P J ; Greco, W R ; Brenner, D E ; Tung, Y ; Ostro, M ; Pilkiewicz, F ; Ginsberg, R ; Petrelli, N
creationdate19930615
lso0119930615
facets
frbrgroupid5952749424508679358
frbrtype5
newrecords20181218
languageeng
creationdate1993
topic
0Adult–Administration & Dosage
1Aged–Adverse Effects
2Doxorubicin–Pharmacokinetics
3Drug Administration Schedule–Chemically Induced
4Drug Carriers–Chemically Induced
5Female–Blood
6Humans–Drug Therapy
7Leukopenia–Metabolism
8Liposomes–Chemically Induced
9Male–Chemically Induced
10Middle Aged–Chemically Induced
11Nausea–Chemically Induced
12Neoplasms–Chemically Induced
13Thrombocytopenia–Chemically Induced
14Vomiting–Chemically Induced
15Drug Carriers
16Liposomes
17Doxorubicin
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Environmental Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Agricultural & Environmental Science Database
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Cowens, J W
1Creaven, P J
2Greco, W R
3Brenner, D E
4Tung, Y
5Ostro, M
6Pilkiewicz, F
7Ginsberg, R
8Petrelli, N
jtitleCancer research
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Cowens
1Creaven
2Greco
3Brenner
4Tung
5Ostro
6Pilkiewicz
7Ginsberg
8Petrelli
aufirst
0J W
1P J
2W R
3D E
4Y
5M
6F
7R
8N
au
0Cowens, J W
1Creaven, P J
2Greco, W R
3Brenner, D E
4Tung, Y
5Ostro, M
6Pilkiewicz, F
7Ginsberg, R
8Petrelli, N
addauCowens, J W
atitleInitial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
jtitleCancer research
risdate19930615
volume53
issue12
spage2796
epage2802
pages2796-2802
issn0008-5472
formatjournal
genrearticle
ristypeJOUR
urlhttp://search.proquest.com/docview/75769112/
eissn15387445
date1993-06-15